SANTORO, Vincenza
 Distribuzione geografica
Continente #
NA - Nord America 560
EU - Europa 518
AS - Asia 77
OC - Oceania 3
SA - Sud America 3
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.164
Nazione #
US - Stati Uniti d'America 559
IE - Irlanda 197
SE - Svezia 170
CN - Cina 71
DE - Germania 32
UA - Ucraina 32
IT - Italia 23
FI - Finlandia 18
PL - Polonia 18
GB - Regno Unito 11
BE - Belgio 8
NL - Olanda 4
FR - Francia 3
AU - Australia 2
CH - Svizzera 2
CL - Cile 2
EG - Egitto 2
IN - India 2
VN - Vietnam 2
BR - Brasile 1
EU - Europa 1
KZ - Kazakistan 1
MX - Messico 1
NZ - Nuova Zelanda 1
PH - Filippine 1
Totale 1.164
Città #
Dublin 197
Chandler 160
Nyköping 85
Jacksonville 65
Ashburn 55
Beijing 34
Dearborn 26
Medford 22
Princeton 22
Ann Arbor 20
Warsaw 18
Cambridge 17
Boardman 13
Des Moines 13
Bremen 11
Messina 11
Brussels 8
Lancaster 8
Jinan 6
New York 6
Washington 5
Enschede 4
Hangzhou 4
Nanjing 4
Ningbo 3
Seattle 3
Shenyang 3
Wilmington 3
Woodbridge 3
Canberra 2
Dong Ket 2
Hebei 2
Livorno 2
Nanchang 2
Norwalk 2
Pune 2
Rome 2
Santiago 2
Tianjin 2
Zurich 2
Auckland 1
Bordeaux 1
Changsha 1
Ciudad Victoria 1
Enna 1
Fantina 1
Florence 1
Fuzhou 1
Guangzhou 1
Haikou 1
Jiaxing 1
Kunming 1
Lappeenranta 1
Mineo 1
Monmouth Junction 1
Oral 1
Palermo 1
Santana de Parnaiba 1
Strasbourg 1
Taizhou 1
Ugong Norte 1
Xiangfen 1
Zhengzhou 1
Totale 874
Nome #
Low-dose of bergamot-derived polyphenolic fraction (BPF) did not improve metabolic parameters in second generation antipsychotics-treated patients: Results from a 60-days open-label study 83
Generic Olanzapine Substitution in Patients with Schizophrenia: Assessment of Serum Concentrations and Therapeutic Response After Switching 69
Aripiprazole augmentation of serotinin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study 64
Pharmacokinetic interaction between duloxetine and second-generation antipsychotics in patients with psychotic disorders 62
Effect of adjunctive duloxetine on the plasma concentrations of clozapine, olazapine and risperidone I patients with psychotic disorders 61
Effetto di un trattamento con risperidone o olanzapina sui livelli serici di prolattina in bambini e adolescenti con patologie psichiatriche. 60
Effect of aripiprazole augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study. 60
Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. 58
Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. 57
ANTITHETIC ACTION OF HYALURONAN 6-MER IN UNDIFFERENTIATED AND DIFFERENTIATED SH-SY5Y CELLS 56
Interactions between antiepileptics and second generation antipsychotics 55
Adverse drug reactions with oral anticoagulants: data from sicilian spontaneous reporting system database 54
Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders 52
Effect of adjunctive duloxetine treatment on the plasma concentrations of clozapine, olanzapine and risperidone in patients with psychotic disorders 51
Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. 50
6-MERS HYALURONAN OLIGOSACCHARIDES STIMULATE INFLAMMATORY RESPONSE IN NEURONAL-LIKE DIFFERENTIATED SH-SY5Y NEUROBLASTOMA CELLS 50
Effect of valproate on plasma concentrations of olanzapine in patients with psychotic disorders , July, 2009, MP 110.. 49
Safety and Tolerability of Antipsychotic Drugs in Pediatric Patients: Data From a 1-Year Naturalistic Study 43
Drug dosage individualization based on a random-effects linear model 36
Vortioxetine on Cognition in Schizophrenia: A Pilot Study 36
Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database 36
Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA trial) 31
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database 16
Totale 1.189
Categoria #
all - tutte 4.153
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.153


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191 0 0 0 0 0 0 0 0 0 1 0 0
2019/2020131 12 6 0 5 0 21 25 12 2 23 23 2
2020/2021149 14 1 38 15 8 15 6 8 8 16 10 10
2021/2022154 6 5 0 2 5 1 10 7 4 46 14 54
2022/2023541 40 65 24 48 47 47 3 33 215 5 12 2
2023/2024130 7 23 15 14 20 29 3 11 8 0 0 0
Totale 1.189